Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01110226 · ClinicalTrials.gov registry record · Phase 1
Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies
A Phase 1 study, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT01110226 is a Phase 1 study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 23 participants.
The verdict
NCT01110226, a Phase 1 study, was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This is a Phase I Clinical Trial. Phase I studies are designed to determine the amount of investigational drugs that can be safely tolerated and to define the side effects that limit the dose. The drug administered in this study is KML-001. It is a highly soluble, orally available arsenic agent. It is currently being tested to determine its effects on telomerase activity. In other words, the purpose of this research study is to find the highest dose of KML001, that can be given without causing severe side effects when it is combined with a standard, commercially available anti-cancer drug called cisplatin.
Interventions
- DRUG Cisplatin
- DRUG KML-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2010-04-27 |
| Est. Completion | 2015-10-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01110226
The ClinicalTrials.gov registry entry for NCT01110226 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cisplatin is the first listed.
NCT01110226 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01110226 about?
NCT01110226 is a clinical study titled "Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies". This is a Phase I Clinical Trial. Phase I studies are designed to determine the amount of investigational drugs that can be safely tolerated and to define the side effects that limit the dose. The drug administered in this study is KML-001. It is a highly soluble, orally available arsenic agent. It ...
What is the current status of trial NCT01110226?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2010-04-27. Estimated completion is 2015-10-27.
What interventions are being tested in trial NCT01110226?
The interventions under investigation include: Cisplatin (DRUG), KML-001 (DRUG).
Who is sponsoring clinical trial NCT01110226?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.